And one for the treatment of Gram+ skin infections.

We are confident that of Concept for Topical Antimicrobial Drug LytixarTM : completion of two Phase I / IIa clinical trialsThe Norwegian pharmaceutical company Lytix Biopharma announces the successful completion of two Phase I / IIa studies with the topical antimicrobial active LytixarTM – one for nasal decolonization MRSA / MSSA bacteria, and one for the treatment of Gram+ skin infections. After Lytix Biopharma CEO Gunnar S cover, We are pleased to announce the successful completion of two clinical trials for our novel antimicrobial LytixarTM known to the spread of antibiotic-resistant bacteria such as MRSA in hospitals. And the community is a serious risk health remains. For the company, a landmark study to provide definitive proof of concept for the powerful bacteriological effect of the novel broad-spectrum, antimicrobial agent LytixarTM.

Every day, whilechase for WFP – big boost for farmers in LesothoThe UN World Food Programme historic historic purchase by buying maize directly from a group of small farmers in Lesotho, the first direct purchase in this country. The farmer produces a surplus despite the country’s worst drought in 30 years by the conservation farming techniques. ‘This is a win-win situation,’said WFP Executive Director Josette Sheeran, speaking of Rome Headquarters of the Agency. ‘It helps income for small farmers while saving money for WFP. ‘.Sure Sensing units to gather sensitive personal information of physiological data to More Information of patients rights activities and sites as, and networked implanted equipment Set patients to new risk should be opponent find ways to control these devices. Source: Carl A.. Of researchers who are on Health Information data protection and security.

Finally, telehealth – technologies to monitor the people and manage their healthcare in the settings outside of hospitals enable – already used to a wide variety of health and wellness targets, such as chronic disease management and an independent ages at.